Compare Danaher Corporation (DHR) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Royal Bank of Canada — how do they compare? Danaher Corporation trades at $219.41 (market cap $152.87B), while Royal Bank of Canada trades at $191.22 (market cap $262.99B). The key difference: Royal Bank of Canada is the larger of the two by market cap, and Royal Bank of Canada pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Royal Bank of Canada for 47 Days on average.
| DHR | RY | |
|---|---|---|
Market Cap | $152.87B | $262.99B |
Volume | 5,228,698 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $242.05 | $217.87 |
52-Week Low | $161.91 | $143.64 |
Typical Hold Time | 69 Days | 47 Days |
Enterprise Value | $175.08B | $730.11B |
Dividend Yield | 0.74% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Royal Bank of Canada (RY) trades at $190.31, down 0.48% with a bearish technical signal despite strong fundamentals. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with a 32.01% net margin, while analyst consensus shows 43% buy ratings amid mixed sentiment.
RY presents a valuation disconnect with solid profitability (17.2% ROE) against bearish technicals. Investment opportunity lies in consistent earnings growth and dividend yield, though risks include stretched valuations and negative cash flow trends. The stock faces headwinds from technical indicators but maintains fundamental strength for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
